[Clinical role of palonosetron for patients receiving cisplatin-based chemotherapy].
Labianca
Roberto
R
Primario, Unità di Oncologia Medica, Ospedali Riuniti, Bergamo.
Mandalà
Mario
M
Clerici
Maurizia
M
D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D008297:Male; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D000077924:Palonosetron; D011812:Quinuclidines / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D013736:Testicular Neoplasms / Q000188:drug therapy; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D007546:Isoquinolines; D011812:Quinuclidines; D012702:Serotonin Antagonists; D000077924:Palonosetron; D002945:Cisplatin